{
    "id": 29482,
    "fullName": "SMARCA4 amp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "SMARCA4 amplification indicates an increased number of copies of the SMARCA4 gene. However, the mechanism causing the increase is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 6597,
        "geneSymbol": "SMARCA4",
        "terms": [
            "SMARCA4",
            "BAF190",
            "BAF190A",
            "BRG1",
            "CSS4",
            "hSNF2b",
            "MRD16",
            "RTPS2",
            "SNF2",
            "SNF2-beta",
            "SNF2L4",
            "SNF2LB",
            "SWI2"
        ]
    },
    "variant": "amp",
    "createDate": "02/26/2019",
    "updateDate": "11/29/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 16190,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, a patient with recurrent high-grade serous ovarian cancer harboring a TP53 I195T mutation and amplifications of ERBB2, CCNE1, PIK3CA, and SMARCA4 was treated with combined Taxol (paclitaxel) and Mektovi (binimetinib) therapy for approximately seven months, followed by Mektovi (binimetinib) alone for two months, and was progression-free at four years post-therapy (PMID: 29844129; NCT01649336).",
            "molecularProfile": {
                "id": 31513,
                "profileName": "CCNE1 amp ERBB2 amp PIK3CA amp SMARCA4 amp TP53 I195T"
            },
            "therapy": {
                "id": 2010,
                "therapyName": "Binimetinib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 2152,
                "name": "ovary epithelial cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14290,
                    "pubMedId": 29844129,
                    "title": "Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29844129"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 31513,
            "profileName": "CCNE1 amp ERBB2 amp PIK3CA amp SMARCA4 amp TP53 I195T",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}